New shunt procedure for correcting
severe heart defect in infants improves survival to one year, but has more complications
Infants born with a severely underdeveloped heart are
more likely to survive to their first birthday when treated with a new shunt procedure
- yet it may not be the safest surgery long term, according to research presented
at the American Heart Association's Scientific Sessions 2009.
Babies born with a critically underdeveloped left side
of their hearts require three surgeries to correct the problem. A portion of the
first operation, the Norwood Procedure, includes a connection to deliver blood
from the heart to the pulmonary arteries feeding the lungs so that blood can pick
up oxygen. There are currently two ways it can be done:
- The new modification of the Norwood utilizes a right ventricle to pulmonary
artery (RV-to-PA) shunt to connect the functioning right ventricle to the pulmonary
artery.
- The traditional version uses a modified Blalock-Taussig shunt (MBTS), which
connects the aorta (the major blood vessel delivering blood from the heart to
the body) to the pulmonary artery.
In a 15-center trial by the Pediatric Heart Network,
555 infants (61 percent male, 73 percent Caucasian) were randomized to receive
either the RV-to-PA shunt or MBTS procedure.
In the first results from the study, the researchers
reported:
- At 12 months, significantly more babies survived without requiring a heart
transplant with the RV-to-PA shunt (74 percent) compared to the MBTS (64 percent,
p=0.01).
- The RV-to-PA shunt had more complications, necessitating 240 interventions
(87.6 for every 100 babies), for example, to make adjustments to the shunt or
use balloons or stents to keep it open. Far fewer cardiovascular interventions
were needed (183, or 66.5 for every 100 babies) in the MBTS group (p=0.006).
- At an average of two years, the transplant-free survival advantage of RV-to-PA
(68 percent) over MBTS (62 percent) had diminished and was no longer significant
(p=0.14).
"Early results seem to favor the RV-PA shunt, but by
two years there is no longer any survival advantage," said Richard G. Ohye, M.D.,
lead author of the study and associate professor of surgery at the University
of Michigan Medical School in Ann Arbor. "It is still unknown which will turn
out to be better over the long term."
For example, the children still must undergo other stages of surgical repair to
increase the amount of oxygen in their blood. Good pulmonary artery growth is
important in the success of this procedure. In the results so far, overall pulmonary
artery growth was significantly greater after the MBTS.
"Ongoing surveillance as these children grow and undergo
the final surgical procedure will be very important to determine the proper roles
of the shunts," Ohye said.
Although rare, having a single working ventricle is the
most common severe congenital heart defect. "Just 25 to 30 years ago, this defect
was uniformly fatal," Ohye said. "Now babies are treated with a series of three
surgeries, but many still die, even when treated at experienced centers."
Each shunt procedure has theoretical advantages, but
researchers previously didn't have hard evidence about which option to choose.
The downside of the MBTS is that it takes blood away from the arteries feeding
the heart muscle. The RV-to-PA shunt doesn't do this, but requires an incision
into the baby's only working ventricle, creating scarring that might interfere
with its later function.
"Roughly 50 percent of surgeons use each type, but we
truly don't know which is better because there has never been a study," Ohye said.
"In fact, there has never been a multi-center, randomized clinical trial performed
in congenital heart surgery. This trial sets a new standard for using evidence-based
medicine to evaluate new procedures in congenital heart surgery."
Co-authors are Sarah Tabbutt, M.D., Ph.D.; Lynn A. Sleeper,
Sc.D.; Gail D. Pearson, M.D., Sc.D.; Lynn Mahony, M.D.; Jane W. Newburger, M.D.,
M.P.H.; Minmin Lu, Ph.D.; Peter C. Laussen, M.B.B.S.; Caren S. Goldberg, M.D.,
M.S.; Nancy W. Ghanayem, M.D.; Peter C. Frommelt, M.D.; Andrew M. Atz, M.D.; Steven
Colan, M.D.; Jeffrey P. Jacobs, M.D.; James Jaggers, M.D.; Kirk R. Kanter, M.D.;
Catherine Dent Krawczeski, M.D.; Alan B. Lewis, M.D.; Brian W. McCrindle, M.D.,
M.P.H.; L. LuAnn Minick, M.D.; Seema Mital, M.D.; Christian Pizarro, M.D.; Chitra
Ravishankar, M.D.; Ismee A. Williams, M.D.; and J. William Gaynor, M.D. Author
disclosures are on the abstract.
The National Heart, Lung, and Blood Institute funded
the study.
|